ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.
DIGITAL HEALTHCARE, MEDICAL DEVICES
Swisslog Healthcare | December 19, 2022
Swisslog Healthcare, a leading supplier in healthcare technology solutions of both medication management and transport automation, has appointed Cory Kwarta as its CEO. Kwarta, who was appointed as CEO of the Swisslog Healthcare – TransLogic division earlier this year, is now entrusted to oversee the global organization, guiding both the company’s TransLogic® and Medication Management divisions.
“Since I started at Swisslog Healthcare, my goal has always been to help improve efficiencies in the healthcare industry. As CEO of the company, I will remain dedicated to our organization’s commitment of helping our customers and partners provide the highest quality healthcare.”
Cory Kwarta was also recently named as a member of Swisslog Healthcare’s Board of Directors. The move came as a result of Kwarta’s recent prior promotion to CEO of Swisslog Healthcare – TransLogic and his 15 years of service with the organization.
Kwarta has a bachelor’s degree in systems engineering from the United States Military Academy at West Point and a master’s degree in business administration from the University of Denver.
Swisslog Healthcare’s TransLogic division works with healthcare facilities to develop custom-designed pneumatic tube systems which automate their needs to transport materials from station to station. The Medication Management division of Swisslog Healthcare assists healthcare facilities with automating and managing the pharmaceutical workflow, including preparation, patient-specific dosing, delivery, and storage. Both divisions deliver operational cost reduction by enabling the redeployment of personnel to patient-facing activities.
About Swisslog Healthcare
Swisslog Healthcare provides integrated medication supply chain solutions to hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patient’s needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways.
HEALTHTECH SECURITY, DIGITAL HEALTHCARE
CereCore® | December 09, 2022
CereCore announced they are expanding their healthcare information technology (IT) services including electronic patient record (EPR), technical and IT staffing services into the United Kingdom in order to support the digital transformation that will help patients, clinicians and carers to manage and view healthcare records.
"For close to 30 years, we have been serving communities in the US by supporting hospitals and clinics through the various stages of healthcare technology adoption from EPR implementations and infrastructure to support. There's momentum in the UK for a single patient record, more clinical decision support and efficient healthcare. CereCore has the skills and expertise needed to help care providers accomplish the tremendous amount of work that lies ahead to meet the NHS regulatory requirements and public health goals," said Curtis Watkins, president and CEO, CereCore.
The international team will employ a range of roles specializing in EPR applications, cloud, network and infrastructure, IT staffing and recruiting, business operations, management and administrative roles. CereCore will also rely upon clinical, EPR and technical experts on their US-based team to assist with digitalisation projects, which will help them quickly ramp up to meet project staffing needs and recruit for specialized technology skillsets.
"We have a US team with decades of experience as nurses, clinicians and healthcare technologists, and they have been consulting on IT projects remotely for years," said Craig McCollum, vice president of MEDITECH international services. "Our vision for expanding internationally is to do our part to improve healthcare delivery by offering what we do best — healthcare technology services. We understand what it takes to appropriately staff technology implementation projects and find the best talent for the job, whether that team member is located locally in the UK, US or elsewhere."
CereCore has been working closely with HCA Healthcare UK and HealthTrust Europe as well as several other leading technology companies. "We expect our partnerships to deepen and to work collaboratively with partners and care systems to provide the services and support needed to create an integrated EPR in the UK," said Watkins.
CereCore® provides IT services that make it easier for you to focus on supporting hospital operations and transforming healthcare through technology. With a heritage rooted in top-performing U.S. hospitals, we serve as leaders and experts in technology, operations, data security, and clinical applications. We partner with clients to become an extension of the team through comprehensive IT and application support, technical professional and managed services, IT advisory services, and EHR consulting, because we know firsthand the power that integrated technology has on patient care and communities.
FUTURE OF HEALTHCARE, MEDICAL DEVICES
Novateur Ventures | December 13, 2022
Novateur Ventures, a leading global life sciences advisory firm and Biotechnology Innovation Organization the world's largest advocacy association for biosciences, research and academic institutions, launched an industry networking information app, Event Guide to JPM 2023, which provides listings for an anticipated >200 satellite networking events taking place during the 41st Annual J.P. Morgan Health Care Conference on January 9-12, 2023, in San Francisco, CA.
The Event Guide to JPM 2023 app, developed by Novateur Ventures and co-managed by BIO, features event search and filter capabilities, provides links to event and registration information, and in the case of in-person events, loads mapping software for directions to the event. Organizations can also use the app to list their scheduled events being held during the conference timeframe.
"It was important for me to develop an app that allowed life science professionals to make important industry connections because, over my career, some of the most transformational relationships I have developed are the direct result of industry networking events. Novateur is delighted to be collaborating with BIO, to give the app a global reach,"
Ali Ardakani, Founder and Managing Director of Novateur Ventures
“I see the app as a natural addition to BIO Partnering at JPM Week. We’re always working to help the industry partner more easily and effectively, and I’m excited to bring the whole JPM Week networking landscape to the palm of your hand. We are excited to be partnering with Novateur on managing and launching this app,” says Mackensie Vernetti, BIO’s Director of Partnering Operations.
About Novateur Ventures
Novateur Ventures is an established life sciences advisory and investment firm with extensive experience in business development and product development of therapeutics, medical devices, and digital health products.
About Biotechnology Innovation Organization
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Good Day BIO is the only daily newsletter at the intersection of biotech, politics and policy. Subscribe here.